Whalesbook
Price War Shuru! Market Mein Hungama
Dekho bhai log, India mein jo weight loss drugs ka market hai na, woh patent expiry ke baad seedha ek price war mein ghus gaya hai. March 20 ko Eli Lilly aur Novo Nordisk ke drugs ke patents India mein khatam ho gaye. Iske baad kya tha, कम से कम six domestic companies ne turant semaglutide ke generic versions launch kar diye. In naye players ne prices itna neeche gira diya hai ki therapy ab bahut zyada accessible ho gayi hai, lekin saath hi market mein doubts aur patient safety ko lekar concerns bhi badh rahe hain.
Generic Drugs Ne Badhai Competition Aur Access
Jab Eli Lilly ke Mounjaro aur Novo Nordisk ke semaglutide wale drugs (Wegovy aur Ozempic) ke patents India mein expire hue, toh generic companies ke liye darwaza khul gaya. Sun Pharma, Dr. Reddy's Laboratories, Lupin, Zydus Lifesciences, Alkem Laboratories, aur Natco Pharma jaise companies ne apne generic semaglutide injections market mein utaar diye hain. Prices itne gir gaye hain ki kuch versions ₹1,290 per month mein mil rahe hain, jabki original brands ₹8,800 se lekar ₹25,000 monthly tak the. Natco Pharma ka injection ₹1,290 mein hai, aur pen device wala ₹4,500 mein aayega. Alkem Laboratories ne toh ₹450 per week (yaani ₹1,800 monthly) mein launch kiya hai. Yeh aggressive pricing market ko boost karegi, aur reports ke hisaab se market ₹1,500 crore se badhkar ₹8,000 crore tak ho sakta hai 2030 tak.
GLP-1 receptor agonist market, jo 2024 mein USD 110.55 million ka tha, woh 2030 tak USD 1,200 million hone wala hai, jo ki 34.3% CAGR se badhega. Semaglutide drugs pehle is market ko dominate karte the, par patent expiry ke baad India jaise price-sensitive market mein adoption aur badhega.
Alkem Laboratories (market cap ₹62,861 crore, P/E 26.2) India mein 4.1% market share rakhti hai. Sun Pharmaceutical Industries (market cap ₹426,386 crore, P/E 39.10) bhi apna generic semaglutide launch karne wali hai. Dr. Reddy's Laboratories (market cap ₹1.09 trillion, P/E 23.4), Lupin, Zydus Lifesciences (market cap ₹89,605 crore, P/E 18.15), Natco Pharma (market cap ₹17,180 crore, P/E 11.0), aur Torrent Pharmaceuticals (market cap ₹145,169 crore, P/E 62.69) bhi is race mein hain. Overall Indian pharma sector FY2026 mein 9-11% grow karega, jiska revenue FY24-25 mein ₹4.72 lakh crore tha.
Misuse Aur Regulatory Risks Ki Chinta
Sasti generic drugs se access toh badh raha hai, par risks bhi hain. Doctors aur activists ko dar hai ki companies galat claims karke ads na karein aur in powerful prescription drugs ko lifestyle aid na bana dein. Yeh drugs ke side effects ho sakte hain, aur Indian drug regulator (CDSCO) ne pehle hi misleading ads aur influencer marketing ke khilaaf warnings di hain.
Zyada competition quality par bhi pressure bana sakta hai. Agar lax oversight raha toh serious issues ho sakte hain. CDSCO ke proposed regulatory changes bhi launches ko delay kar sakte hain.
Original companies jaise Novo Nordisk aur Eli Lilly ke liye India mein patent loss, dusre markets ke liye bhi ek example ban sakta hai, jisse unke global revenue ko impact ho sakta hai.
Future Kya Kehta Hai?
Analysts ko lagta hai ki low-cost generics India mein weight-loss drug market ko double kar denge. Par, growth tabhi maintain hogi jab companies strict guidelines follow karein aur patient safety ka dhyan rakhein. AI aur digital health platforms bhi long-term access badha sakte hain. Market 2033 tak INR 4,564 crore tak pahunch sakta hai, agar regulatory oversight strong raha.